{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:25:29Z","timestamp":1794327929751,"version":"4.9.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The number and timing of pneumococcal conjugate vaccine (PCV) primary doses can impact infant immune responses. This descriptive post hoc analysis evaluates the 20-valent PCV (PCV20) immunogenicity by vaccination timing in healthy infants in 2 key phase 3 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Immunogenicity endpoints from Study B7471012 comparing PCV20 to 13-valent PCV (PCV13) in a 2\u2009+\u20091 schedule were examined by dosing regimen subgroup: the 2,4m subgroup (vaccinations at 2, 4 and 11\u201312 months of age) and the 3,5m subgroup (vaccinations at 3, 5 and 11\u201312 months). Additionally, immune responses from the 2\u2009+\u20091 schedule were compared descriptively with those in Study B7471011, in which participants received PCV20 or PCV13 in a 3\u2009+\u20091 schedule at ~2, 4, 6 and 12\u201315 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this descriptive analysis, serotype-specific serum immunoglobulin G (IgG) responses in the PCV20 3,5m subgroup were higher than those in the 2,4m subgroup across all 20 vaccine serotypes and comparable to PCV13 immune responses in the 2,4m subgroup. Regardless of primary dose timing, PCV20 2\u2009+\u20091 elicited strong booster immune responses with post-toddler dose IgG levels similar to a 3\u2009+\u20091 schedule. A stratified analysis showed little evidence of effect modification by maternal Tdap vaccination status. PCV20 was safe and well tolerated in both the 2,4m and 3,5 m subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this descriptive analysis of the 2\u2009+\u20091 schedule, a 1-month delay in PCV20 priming to 3 and 5 months was associated with improved immune responses comparable to those of PCV13 at 2 and 4 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005291","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:00:36Z","timestamp":1781064036000},"page":"1089-1096","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series Doses"],"prefix":"10.1097","volume":"45","author":[{"given":"Mary","family":"Kline","sequence":"first","affiliation":[{"name":"Vaccine Research and Development, Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Wyllie","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"McElwee","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trammel","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Sabra","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calman A.","family":"MacLennan","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Ltd, Marlow, UK (affiliation at the time of the study)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Theilacker","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Pharma GmbH, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Mo\u00efsi","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"R1-20261110","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"18","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R2-20261110","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1016\/j.vaccine.2020.08.068","article-title":"Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis.","volume":"38","author":"Chapman","year":"2020","journal-title":"Vaccine"},{"key":"R3-20261110","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/j.vaccine.2022.06.024","article-title":"Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.","volume":"40","author":"Huang","year":"2022","journal-title":"Vaccine"},{"key":"R4-20261110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis.","volume":"25","author":"Garcia Quesada","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"R5-20261110","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/ciaa917","article-title":"Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation.","volume":"72","author":"Cohen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R6-20261110","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/cid\/ciw067","article-title":"Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine.","volume":"62","author":"Tomczyk","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R7-20261110","doi-asserted-by":"crossref","first-page":"60.e9","DOI":"10.1016\/j.cmi.2015.08.027","article-title":"Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA.","volume":"22","author":"Metcalf","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R8-20261110","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study.","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"key":"R9-20261110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/cid\/cix310","article-title":"Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006-2014.","volume":"65","author":"Oligbu","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R10-20261110","doi-asserted-by":"crossref","first-page":"e0177113","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis.","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS One"},{"key":"R11-20261110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/21645515.2015.1118593","article-title":"Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement.","volume":"12","author":"Hausdorff","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R12-20261110","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/21645515.2016.1277300","article-title":"Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world.","volume":"13","author":"Cui","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R18-20261110","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/INF.0000000000004334","article-title":"A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants.","volume":"43","author":"Senders","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20261110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/INF.0000000000004300","article-title":"Phase 3 safety and immunogenicity study of a three-dose series of twenty-valent pneumococcal conjugate vaccine in healthy infants and toddlers.","volume":"43","author":"Korbal","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20261110","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1080\/21645515.2016.1157239","article-title":"What timing of vaccination is potentially dangerous for children younger than 2 years?","volume":"12","author":"Gras","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R23-20261110","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/INF.0000000000000079","article-title":"Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.","volume":"33","author":"Deloria Knoll","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R24-20261110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/INF.0b013e3181c67f04","article-title":"Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom.","volume":"29","author":"Goldblatt","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20261110","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.2013.228052","article-title":"Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.","volume":"310","author":"Spijkerman","year":"2013","journal-title":"JAMA"},{"key":"R26-20261110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3345\/cep.2019.01739","article-title":"Pneumococcal conjugate vaccines: choice of schedule and product development.","volume":"63","author":"Lee","year":"2020","journal-title":"Clin Exp Pediatr"},{"key":"R27-20261110","doi-asserted-by":"crossref","first-page":"e00128","DOI":"10.1128\/mSphere.00128-18","article-title":"Development and validation of 13-plex Luminex-based assay for measuring human serum antibodies to Streptococcus pneumoniae capsular polysaccharides.","volume":"3","author":"Pavliakova","year":"2018","journal-title":"mSphere"},{"key":"R28-20261110","doi-asserted-by":"crossref","first-page":"e00127","DOI":"10.1128\/mSphere.00127-18","article-title":"Evaluation of a validated Luminex-based multiplex immunoassay for measuring immunoglobulin G antibodies in serum to pneumococcal capsular polysaccharides.","volume":"3","author":"Tan","year":"2018","journal-title":"mSphere"},{"key":"R29-20261110","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1080\/21645515.2020.1753438","article-title":"Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine.","volume":"16","author":"Chapman","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"R30-20261110","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1093\/cid\/ciz1164","article-title":"Dose-specific effectiveness of 7- and 13-valent pneumococcal conjugate vaccines against vaccine-serotype Streptococcus pneumoniae colonization in children.","volume":"71","author":"Lewnard","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R31-20261110","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/infdis\/174.6.1271","article-title":"Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine.","volume":"174","author":"Dagan","year":"1996","journal-title":"J Infect Dis"},{"key":"R32-20261110","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/j.vaccine.2024.04.061","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study.","volume":"42","author":"Andrejko","year":"2024","journal-title":"Vaccine"},{"key":"R33-20261110","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"R34-20261110","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/INF.0000000000000076","article-title":"Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers.","volume":"33","author":"Whitney","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R35-20261110","doi-asserted-by":"crossref","first-page":"e1001839","DOI":"10.1371\/journal.pmed.1001839","article-title":"The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries.","volume":"12","author":"Flasche","year":"2015","journal-title":"PLoS Med"},{"key":"R36-20261110","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/INF.0000000000001601","article-title":"Pneumococcal immune response in infants whose mothers received tetanus, diphtheria and acellular pertussis vaccination during pregnancy.","volume":"36","author":"Maertens","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R37-20261110","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/AOG.0000000000002301","article-title":"718: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination.","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R38-20261110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1473-3099(17)30654-0","article-title":"Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1\u2009+\u20091) compared with two primary doses and a booster (2\u2009+\u20091) in UK infants: a multicentre, parallel group randomised controlled trial.","volume":"18","author":"Goldblatt","year":"2018","journal-title":"Lancet Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:01:26Z","timestamp":1794326486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005291","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"2025-12-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}